This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frankenfeld, C. L. Articles by Lampe, J. W. Search for Related Content PubMed PubMed Citation Articles by Frankenfeld, C. L. Articles by Lampe, J. W.

Mammographic Density in Relation to Daidzein-Metabolizing Phenotypes in Overweight, Postmenopausal Women

¹ Cancer Prevention Program, ² Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington; Departments of ³ Epidemiology and ⁴ Medicine, ⁵ Interdisciplinary Program in Nutritional Sciences, University of Washington, Seattle, Washington; and ⁶ Group Health Cooperative, Seattle, Washington

Requests for reprints: Johanna W. Lampe, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N. MP-900, Box 19024, Seattle, WA 98109. Phone: (206) 667-6580; Fax: (206) 667-7850. E-mail: jlampe{at}fhcrc.org

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Circulating hormones are associated with mammographic density, an intermediate marker of breast cancer risk. Differences in circulating hormones, including estrone and testosterone, have been observed in premenopausal women based on their capacity to metabolize daidzein, an isoflavone found predominantly in soybeans. Equol and O-desmethylangolensin (O-DMA) are products of intestinal bacterial metabolism of daidzein. There is interindividual variability in the capacity to produce daidzein metabolites; individuals can be equol producers or non-producers and O-DMA producers or non-producers. We tested the hypothesis that daidzein-metabolizing phenotypes are associated with mammographic density. Participants were recruited from among 92 sedentary, postmenopausal women, ages 50 to 75 years, who participated in a 1-year physical activity intervention. Pre-intervention mammographic density was determined using a computer-assisted, gray-scale thresholding technique. Fifty-five of these women consumed supplemental soy protein (>10 mg daidzein/d) for 3 days and collected a first-void urine sample on the fourth day to determine daidzein-metabolizing phenotypes. Equol and O-DMA concentrations were measured using gas chromatography-mass spectrometry. Associations between daidzein-metabolizing phenotypes and percent mammographic density were adjusted for age, maximum adult weight, gravidity, family history of breast cancer, and serum follicle-stimulating hormone and free testosterone concentrations. Mammographic density was 39% lower in equol producers compared with non-producers (P = 0.04). O-DMA producers had mammographic density 69% greater than non-producers (P = 0.05). These results suggest that particular intestinal bacterial profiles are associated with postmenopausal mammographic density, and these associations are not entirely explained by differences in reproductive or anthropometric characteristics or circulating hormones.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Mammographic density has been positively associated with breast cancer risk (1-3). Although the mechanism underlying the relationship between mammographic density and risk of breast cancer has not been fully explained, several hormone-related factors have been associated with mammographic density changes, including decreased density with contraceptive hormone use (4) and use of the anti-estrogen tamoxifen (5-7), and increased density with non-contraceptive exogenous sex hormone use (8-10). Mammographic tissue has been observed to be less radiologically dense during the follicular phase of the menstrual cycle (11), a period characterized by increasing estrogen secretion (12). In postmenopausal women, percent mammographic density was positively associated with sex hormone binding globulin and progesterone and inversely associated with free estradiol (13). Nulliparous women and women with a later age at first birth were observed to have denser breasts than women who had children at a young age (14-19), a difference found even among postmenopausal women (14).

Intestinal bacteria are important in the metabolism of reproductive hormones (20), but whether particular bacterial profiles are associated with mammographic density has not been studied. Particular intestinal bacteria are capable of metabolizing the soy isoflavone daidzein to equol or O-desmethylangolensin (O-DMA). Humans are considered equol producers if they harbor bacteria capable of metabolizing daidzein to equol, and similarly O-DMA producers are individuals who harbor bacteria that can metabolize daidzein to O-DMA. Although the intestinal bacteria that can metabolize daidzein to equol or to O-DMA have not yet been identified, the presence or absence of these metabolites in urine can serve as markers of particular intestinal bacteria. Animal studies suggest that equol-producing capacity is present in all members of other mammalian species (21-23). In contrast, the prevalence of equol producers is approximately 30% to 50% in human populations (24-27). The prevalence of O-DMA producers is approximately 80% to 90% among humans (24, 28). Results from a study of premenopausal women suggest that equol-producing women have lower circulating concentrations of estrogens and androgens (29). On the basis of these observations, we tested the hypothesis that percent mammographic density, a hormone-associated intermediate marker of breast cancer risk, is influenced by the equol-producer phenotype. Although relationship between steroid hormones and the O-DMA-producer phenotype has not been reported, we also examined the association between mammographic density and O-DMA-producer phenotype.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Subjects and Experimental Design
Participants were recruited from women who participated in the Physical Activity for Total Health Study (parent study), a study designed to examine the effect of adopting a moderate intensity exercise program (compared with a stretching program) on the reproductive hormone profile in overweight [body mass index (BMI) 25 or BMI between 24 and 25 if body fat >33%], sedentary, postmenopausal [having no menstrual periods in prior year or follicle-stimulating hormone (FSH) > 30 mIU/mL for women who had hysterectomy] women. Details about study procedures and inclusion and exclusion criteria are published elsewhere (30). Briefly, women eligible for participation in the parent study were non-smokers; moderate or non-drinkers (two or fewer alcoholic drinks per day); physically able to undertake a moderate physical activity program; not using any exogenous hormone medications; free from diabetes mellitus or significant endocrine abnormalities; and free of prevalent cancers. Before randomization, data about demographics and reproductive history information were collected via self-administered questionnaire, and urine and blood samples were obtained.

Of the 173 women who participated in the parent study, 92 women participated in an ancillary mammographic density study; of these 92 women, 34 women did not participate in the present study (daidzein-metabolizing phenotyping) for the following reasons: unable to locate (n = 10), consented but did not complete study (n = 4), indicated willingness to participate during telephone call but did not return consent (n = 5), lack of interest (n = 5), and declined but no reason given (n = 10). Fifty-eight women completed the daidzein-metabolizing phenotyping.

Mammographic density was determined from screening mammograms taken in the year before randomization (n = 42) or within 1 month post-randomization (n = 16) in the parent study. An additional exclusion criterion for the mammographic density study was hormone use in the year before randomization in the parent study. There was an approximately 2 to 3 years time difference between baseline data collection (including mammographic density) for the parent study and collection of urine for daidzein-metabolizing phenotyping. Exclusion criteria for participation in the equol/O-DMA-producer phenotyping were known allergy to soy and chronic antibiotic therapy. Women who were taking acute antibiotic therapy were scheduled for phenotyping 3 months after the completion of antibiotic therapy. The Institutional Review Board at the Fred Hutchinson Cancer Research Center approved all procedures and written, informed consent was obtained from all participants.

Study Procedures
Women were mailed three soy protein bars and a urine collection kit. On each of three consecutive days, each woman supplemented her usual diet with either one soy protein bar (Revival Soy, Physicians Laboratories, Winston-Salem, NC, 83 mg daidzein per day) or one third of a package of soy nuts (GeniSoy, Fairfield, CA, 10 mg daidzein per day). On the morning of the fourth day, the woman collected a sample (50 to 80 mL) of first-void urine, and mailed the sample to the Fred Hutchinson Cancer Research Center. Urinary equol and O-DMA concentrations are stable at room temperature for 14 days.7

Mammographic Density
Mammographic images were digitized for percent density, using a computerized interactive density thresholding technique with a graphics overlay (31, 32). One trained technician (E.A.), blinded to daidzein-metabolizing phenotypes, determined mammographic density for all women in the parent study. A 10% random, blinded sample of mammographic images was re-read to evaluate reliability. The intraclass correlation for repeated mammographic percent density determinations was 0.88. A gray area was selected as a threshold to separate the outside edge of the breast from the background, which was used to determine the total breast area. The back of the breast was defined by outlining any pectoral muscle, which was then excluded from the final calculation. The edges of the regions that are representative of radiologically dense tissue in the image are identified by the selection of a second threshold, the sum of which provides the area of density in the breast. Dense tissue is typically brighter than fat, which shows up as a darker gray or black. Percent density was calculated as the proportion of the area of density in the breast relative to the total breast area.

Daidzein-Metabolizing Phenotypes
Urinary equol and O-DMA were analyzed using a variation of the ether extraction method of Heinonen et al. (33). Urine samples, frozen and stored at –70°C until analysis, were ether-extracted and analyzed by gas chromatography-mass spectrometry as described elsewhere.⁷ Quality control urine samples were included in each batch. The mean intra-assay coefficient of variations for equol and O-DMA in the quality control urine samples, measured in duplicate in each batch, were <7%. Given the sensitivity of the assay, urine concentrations less than 182 nmol/L (44 ng/mL in urine) of equol and 170 nmol/L (44 ng/mL in urine) of O-DMA were considered below detectable limit. Equol/O-DMA producers were defined as individuals with any detectable concentration of equol/O-DMA. All women had detectable concentrations (>44 ng/mL in urine) of genistein (minimum: 100 ng/mL) and of daidzein (minimum: 90 ng/mL), indicating compliance with the soy consumption protocol in all women.

Statistical Analysis
Three women were excluded from analysis because of poor mammogram image quality for both breasts, leaving a final sample size of 55 for analysis. Mean percent breast density of left and right breasts was used as a summary measure of percent breast density in 50 women. The value of left breast (n = 1) or the right breast (n = 4) only was used for women whose mammogram image quality was considered poor for the contralateral breast. Before analysis, natural logarithmic transformations were done for all variables that appeared to be skewed, including percent mammographic density. Linear regression was used to model associations between covariates and mammographic density. Linear regression was used to estimate differences in percent mammographic density by equol/O-DMA-producer phenotypes separately and combined using six models for the separate phenotypes and five models for the combined phenotype: (1) unadjusted; (2) adjusted for age; (3) adjusted for age and the other daidzein-metabolizing phenotype (not in the model for combined phenotype); (4) adjusted for age and serum hormone concentrations; (5) adjusted for age and reproductive and anthropometric factors; and (6) adjusted for age, reproductive and anthropometric factors, and serum hormone concentrations. Combined phenotypes were classified as equol non-producer/O-DMA non-producer (equol–/O-DMA–), equol non-producer/O-DMA producer (equol–/O-DMA+), equol producer/O-DMA non-producer (equol+/O-DMA–), and equol producer/O-DMA producer (equol+/O-DMA+). Variables for adjustment were chosen from selected anthropometric, lifestyle, and reproductive characteristics and circulating hormone and sex hormone binding globulin concentrations (SHBG) concentrations (measured at baseline of parent study) using a best-fit model procedure based on forward stepwise regression. Specifically, univariate regression models were fit for each of these variables with percent mammographic density as the outcome. Variables with a model P value < 0.3 were included in a forward stepwise regression [P value for entry (pe) = 0.1] by category (anthropometric, lifestyle, hormonal, and reproductive). For each category, the best-fit model was identified. Variables from each of the category models were included together for an overall multivariate adjustment of each phenotype on percent mammographic density using linear regression. The specific variables considered were BMI, clinic-measured current weight, DEXA-measured percent body fat, intentional loss of >10 pounds in past 20 years, reported maximum adult height, reported maximum adult weight, circulating estrone, FSH, testosterone, free testosterone, androstenedione, estradiol, free estradiol, DHEA, DHEA-sulfate and SHBG, urinary 2-hydroxyestrone:16-hydroxyestrone, percent dietary calories from fat, smoking status (never/former), ever/never use of non-contraceptive exogenous estrogen, years of exogenous estrogen use, ever/never oral contraceptive use, years of oral contraceptive use, gravidity, age at first pregnancy, previous hysterectomy, previous oopherectomy, type of menopause (surgical, natural, or other), ever breastfed for more than 1 month, age at first menses, menstrual regularity in premenopausal period, and family history of breast cancer (mother, sister, aunt, or daughter). Measurement of these variables is reported elsewhere (30). Analyses were done using Stata 7.0 (Stata Corporation, College Station, TX).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Twelve women were classified as equol-producers (25%) and 45 women were classified as O-DMA producers (82%). There was no apparent relationship between equol-producer and O-DMA-producer phenotype classifications in this sample of women (² P value = 0.73): 10 (18%) individuals were equol producers as well as O-DMA producers (equol+/O-DMA+), 8 (15%) equol non-producer plus O-DMA non-producer (equol–/O-DMA–), 2 (4%) equol +/O-DMA–, and 35 (64%) equol–/O-DMA+. Eighty-three percent of equol producers and 81% of equol non-producers were O-DMA producers.

Participant demographic, anthropometric, and reproductive characteristics by daidzein-metabolizing phenotypes are presented in Table 1. Women were, on average, 60 years of age, were well educated (n = 28 having post-graduate education), and most women indicated their racial background to be Caucasian (n = 51). No differences in age, education, or racial affiliation were observed between producers and non-producers within either daidzein-metabolizing phenotype. Twenty-nine (53%) women were former smokers. Former smokers were approximately three times as likely as never smokers to be equol producers than equol non-producers [odds ratio = 3.5, 95% confidence interval (CI): 0.7-22.1]. Similarly, formers smokers were approximately six times as likely to be O-DMA producers than O-DMA non-producers (odds ratio = 6.0, 95% CI: 1.0-62.0).

Inverse associations with percent mammographic density were observed with anthropometric characteristics BMI [ß-coefficient (ß) = –0.10 (95% CI: –0.16 to –0.04)], log-transformed maximum adult weight [ß = –3.04 (95% CI: –4.36 to –1.72)], and current weight [ß = –0.04 (95% CI: –0.05 to –0.02)], and with previous oopherectomy [ß = –0.84 (95% CI: –1.64 to –0.04)]. Women with a family history of breast cancer in a first- or second-degree female relative had greater percent mammographic density [ß = 0.53 (95% CI: 0.01-1.04)] than women without such family history. Age at first menstrual period [ß = 0.04 (95% CI: –0.07 to 15.3)], being nulligravid [ß = 0.45 (95% CI: –0.23 to 1.13)], and natural menopause (versus surgical) [ß = 0.29 (95% CI: –0.29 to 0.88)] were non-statistically significantly positively associated with percent mammographic density. Ever use of oral contraceptives [ß = –0.42 (95% CI: –0.99 to 0.15)], ever use of non-contraceptive exogenous estrogen [ß = –0.33 (95% CI: –0.84 to 0.18)] and previous hysterectomy [ß = –0.14 (95% CI: –0.76 to 0.49)] were non-statistically significantly inversely associated with percent mammographic density. No association between smoking status (former/never) with mammographic density was observed [ß = 0.003 (95% CI: –0.52 to 0.52)].

Unadjusted geometric mean mammographic density was lower in equol producers than non-producers (Table 2), and this was independent of age and O-DMA-producer phenotype. Adjustment for gravidity, maximum adult weight (r = 0.92 correlation with current weight), and family history of breast cancer attenuated this difference. In contrast, after adjusting for FSH and free testosterone (the hormones identified as the strongest predictors of mammographic density from the best-fit model procedure), a larger difference between equol producers and equol non-producers was observed.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Because endogenous hormones have been associated with mammographic density in pre- and postmenopausal women (13), we hypothesized that mammographic density differences between equol-producing and non-producing women may be mediated by hormonal differences. However, adjustment for FSH and free testosterone concentrations (stronger than circulating estrogens and SHBG as statistical predictors of mammographic density in this study) did not attenuate the association between equol-producer phenotype and mammographic density. Thus, the association we observed seems not to be mediated through circulating concentrations of these hormones.

In our analysis, O-DMA-producing women had adjusted mammographic density approximately 69% greater than that of O-DMA non-producing women. Little is known about the physiologic effects associated with the O-DMA-producer phenotype, and we are unaware of other studies that have specifically evaluated mammographic density in relation to O-DMA-producer phenotype. We observed that adjustment for selected circulating hormone concentrations markedly attenuated the association between the O-DMA-producer phenotype and mammographic density, suggesting that endogenous hormones, in part, modulate the association.

These daidzein-metabolizing phenotypes are markers of the presence of particular intestinal bacteria profiles capable of metabolizing daidzein to equol/O-DMA. Although the mechanism by which the intestinal bacteria, and specifically the daidzein-metabolizing phenotypes, could influence mammographic density is not known, we propose several hypotheses. One hypothesis is that circulating equol and O-DMA, which can bind to estrogen receptors and ß (34, 35), may influence mammographic density. However, this hypothesized mechanism may not be physiologically relevant in low-soy consuming populations, such as postmenopausal women in the United States (36, 37). Whether exposure to low levels of daidzein metabolites would result in clinically relevant physiologic effects remains to be established. A second hypothesis is that these daidzein-metabolizing phenotypes may arise as a result of exogenous factors that concurrently and separately influence intestinal environment and mammographic density. Similarly, a third hypothesis is that these daidzein-metabolizing phenotypes may be markers of a genetic profile that is associated with intestinal environment and mammographic density. In these latter two hypotheses, the daidzein-metabolizing phenotypes serve as surrogate markers of other factors influencing mammographic density. A fourth hypothesis is that there are differences in metabolic capacities of equol/O-DMA-producing and non-producing bacteria. Bacteria responsible for daidzein-metabolizing phenotypes in humans have not been definitively established. However, strain-specific metabolism of reproductive hormones has been observed between other bacteria (38). Differences in intestinal bacterial populations may result in different reproductive hormone metabolite profiles, and, thus, differing concentrations of metabolites available for reabsorption, an effect that could influence circulating concentrations of some hormones within the human host. A final hypothesis is that the presence of daidzein-metabolizing bacteria is correlated with the presence of other bacteria that also thrive in a particular intestinal environment or that the presence of daidzein-metabolizing bacteria may influence the capacity for other bacteria to colonize the intestinal tract. If this other (not daidzein-metabolizing) bacteria were to influence mammographic density through some mechanism, the daidzein-metabolizing bacteria could be indirectly associated with mammographic density. These hypothesized mechanisms are not mutually exclusive, and it is possible that intestinal bacteria may influence mammographic density through several mechanisms. Also, the mechanisms by which each of the daidzein-metabolizing phenotypes is associated with mammographic density may be different.

The overall average percent mammographic density in this group of women was 4%. This value is lower than reported in other studies. However, this study population is very different from many of the populations reported in the literature. Vachon et al. (19) observed a mean of 32% (SD: 14) mammographic density in first-degree and second-degree female relatives of breast cancer cases, Maskarinec et al. (39) observed a mean of 28% (SD: 20) in premenopausal and postmenopausal Caucasian women, Ursin et al. (40) observed a median percent mammographic density of 20% (interquartile range: 8 to 38) in women 50 years or age and older and without family history of breast cancer, and Gapstur et al. (41) observed mean percent density of 15% (SD: 9) in postmenopausal Hispanic women. All women in our study were postmenopausal and overweight or obese, with an average BMI of 30, and did not use hormone treatment in the 6 months before randomization. Hormone therapy regimens and lower BMI are factors that have been associated with greater postmenopausal mammographic density (8, 14, 41); thus, women in our study would be expected to have low mammographic density, compared with women in these other studies. Despite the low values, percent mammographic density was associated with several characteristics as expected. Notably, percent mammographic density was positively associated with family history of breast cancer and being nulligravid and was inversely associated with BMI and current weight, which has been observed in other studies (14, 19, 42). Similar to our finding, former hormone use, compared with never use, has not been a strong determinant of postmenopausal mammographic density in other studies (14, 19, 41). Although not statistically significant, we observed that age at menarche and surgical menopause were both inversely associated with percent mammographic density, which is the same direction of the association observed in other studies (14, 41). Overall, this suggests that, despite the low values, the percent mammographic density measure in our study was valid.

Our study has some limitations. One, given the small sample of women, we were not able to estimate precisely the magnitude of association between daidzein-metabolizing phenotypes and mammographic density and we also may have failed to identify some true associations. However, we know of no other studies to date that have evaluated the association between mammographic density and daidzein-metabolizing phenotypes. This preliminary work provides a foundation for further study in which to confirm and more precisely estimate the magnitude of association between daidzein-metabolizing phenotypes and mammographic density. Two, the parent study was a randomized trial, and the women were selected for the parent study based on particular selection criteria, which may have also reduced variability in our outcomes and decreased the power to detect associations in this ancillary study.

In summary, we observed that postmenopausal percent mammographic density, an intermediate marker of breast cancer risk, was lower in equol producers compared with non-producers and was higher in O-DMA producers than non-producers. Further adjustment for covariates suggested that the equol-producer phenotype may influence mammographic density, in part, through anthropometric and/or reproductive characteristics and that the O-DMA-producer phenotype may influence mammographic density, in part, through circulating FSH and free testosterone concentrations. Additionally, the association of each daidzein-metabolizing phenotype with mammographic density appeared to be independent of the other phenotype. These results should be confirmed with a larger sample size, and evaluation in other age groups and populations is also warranted.

	Acknowledgments

 
We are grateful to Lynda McVarish for her assistance with the study databases. Deuterated standards for the analysis of equol and O-DMA were prepared and provided by Kristiina Wähälä and Tuija Jokela, University of Helsinki, Helsinki, Finland.

	Footnotes

 
Grant support: NIH R03CA097475 and R01CA69334, and Institutional Research Training grant T32CA009168, and institutional funding from the Fred Hutchinson Cancer Research Center.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

⁷ CL Frankenfeld, C Atkinson, WK Thomas, E Goode, A Gonzalez, T Jokela, K Wähälä, SM Schwartz, SS Li, JW Lampe. Familial correlations, segregation analysis and non-genetic correlates of soy isoflavonemetabolizingphenotypes, submitted for publication.

Received 12/10/03; revised 1/30/04; accepted 2/ 9/04.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Saftlas AF, Hoover RN, Brinton LA, et al. Mammographic densities and risk of breast cancer. Cancer 1991;67:2833-8.[CrossRef][Medline]
2. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.[Abstract/Free Full Text]
3. Byrne C, Schairer C, Brinton LA, et al. Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes & Control 2001;12:103-10.[CrossRef][Medline]
4. Spicer DV, Ursin G, Parisky YR, et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-6.[Abstract/Free Full Text]
5. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol, Biomarkers & Prev 1999;8:863-6.[Abstract/Free Full Text]
6. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol, Biomarkers & Prev 2000;9:911-5.[Abstract/Free Full Text]
7. Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol, Biomarkers & Prev 2000;9:917-21.[Abstract/Free Full Text]
8. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.[Abstract/Free Full Text]
9. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6.[Abstract/Free Full Text]
10. Leung W, Goldberg F, Zee B, Sterns E. Mammographic density in women on postmenopausal hormone replacement therapy. Surgery 1997;122:669-3.[CrossRef][Medline]
11. White E, Velentgas MT, Lehman CD, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 1998;90:906-10.[Abstract/Free Full Text]
12. Mishell DR Jr, Nakamura RM, Crosignani PG, et al. Serum gonadotropin and steroid patterns during the normal menstrual cycle. Am J Obstet Gynecol 1971;111:60-5.[Medline]
13. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002;87:876-82.[CrossRef][Medline]
14. El-Bastawissi AY, White E, Mandelson MT, Taplin SH. Reproductive and hormonal factors associated with mammographic breast density by age (United States). Cancer Causes & Control 2000;11:955-63.[CrossRef][Medline]
15. Bergkvist L, Tabar L, Bergstrom R, Adami HO. Epidemiologic determinants of the mammographic parenchymal pattern. A population-based study within a mammographic screening program. Am J Epidemiol 1987;126:1075-81.[Abstract/Free Full Text]
16. Gram IT, Funkhouser E, Tabar L. Reproductive and menstrual factors in relation to mammographic parenchymal patterns among perimenopausal women. Br J Cancer 1995;71:647-50.[Medline]
17. Kaufman Z, Garstin WI, Hayes R, Michell MJ, Baum M. The mammographic parenchymal patterns of nulliparous women and women with a family history of breast cancer. Clin Radiol 1991;43:385-8.[Medline]
18. van Gils CH, Hendriks JH, Otten JD, Holland R, Verbeek AL. Parity and mammographic breast density in relation to breast cancer risk: indication of interaction. Eur J Cancer Prev 2000;9:105-11.[CrossRef][Medline]
19. Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes & Control 2000;11:653-62.[CrossRef][Medline]
20. Adlercreutz H, Martin F, Pulkkinen M, et al. Intestinal metabolism of estrogens. J Clin Endocrinol & Metab 1976;43:497-505.[Abstract]
21. Adlercreutz H, Musey PI, Fotsis T, et al. Identification of lignans and phytoestrogens in urine of chimpanzees. Clin Chim Acta 1986;158:147-54.[CrossRef][Medline]
22. King RA. Daidzein conjugates are more bioavailable than genistein conjugates in rats. Am J Clin Nutr 1998;68:1496S-9S.[Abstract]
23. Bannwart C, Adlercreutz H, Wähälä K, et al. Identification of the phyto-oestrogen 3',7-dihydroxyisoflavan, an isomer of equol, in human urine and cow's milk. Biomed Environ Mass Spectrom 1988;17:1-6.[CrossRef][Medline]
24. Arai Y, Uehara M, Sato Y, et al. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 2000;10:127-35.[Medline]
25. Kelly GE, Nelson C, Waring MA, Joannou GE, Reeder AY. Metabolites of dietary (soya) isoflavones in human urine. Clin Chim Acta 1993;223:9-22.[CrossRef][Medline]
26. Hutchins AM, Slavin JL, Lampe JW. Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. J Am Diet Assoc 1995;95:545-51.[CrossRef][Medline]
27. Akaza H, Miyanaga N, Takashima N, et al. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 2002;32:296-300.[Abstract/Free Full Text]
28. Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA. The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med 1995;208:40-3.[Abstract]
29. Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, Kurzer MS. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol, Biomarkers & Prev 2000;9:581-6.[Abstract/Free Full Text]
30. McTiernan A, Ulrich CM, Yancey D, et al. The Physical Activity for Total Health (PATH) Study: rationale and design. Med Sci Sports Exerc 1999;31:1307-12.[Medline]
31. Boyd NF, Greenberg C, Lockwood G, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 1997;89:488-96.[Abstract/Free Full Text]
32. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. Automated analysis of mammographic densities. Phys Med Biol 1996;41:909-23.[CrossRef][Medline]
33. Heinonen S, Wähälä K, Adlercreutz H. Identification of isoflavone metabolites dihydrodaidzein, dihydrogenistein, 6'-OH-O-dma, and cis-4-OH-equol in human urine by gas chromatography-mass spectroscopy using authentic reference compounds. Anal Biochem 1999;274:211-9.[CrossRef][Medline]
34. Schmitt E, Dekant W, Stopper H. Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro 2001;15:433-9.[CrossRef][Medline]
35. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors and ß. Biol Pharm Bull 2001;24:351-6.[CrossRef][Medline]
36. de Kleijn MJJ, van der Schouw YT, Wilson PWF, et al. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: The Framingham Study. J Nutr 2001;131:1826-32.[Abstract/Free Full Text]
37. Frankenfeld CL, Patterson RE, Horner NK, et al. Validation of a soy food-frequency questionnaire and evaluation of correlates of plasma isoflavone concentrations in postmenopausal women. Am J Clin Nutr 2003;77:674-80.[Abstract/Free Full Text]
38. Järvenpää P, Kosunen T, Fotsis T, Adlercreutz H. In vitro metabolism of estrogens by isolated intestinal micro-organisms and by human faecal microflora. J Steroid Biochem 1980;13:345-9.[Medline]
39. Maskarinec G, Nagata C, Shimizu H, Kashiki Y. Comparison of mammographic densities and their determinants in women from Japan and Hawaii. Int J Cancer 2002;102:29-33.[CrossRef][Medline]
40. Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol, Biomarkers & Prev 2003;12:332-8.[Abstract/Free Full Text]
41. Gapstur SM, Lopez P, Colangelo LA, Wolfman J, Van Horn L, Hendrick RE. Associations of breast cancer risk factors with breast density in Hispanic women. Cancer Epidemiol, Biomarkers & Prev 2003;12:1074-80.[Abstract/Free Full Text]
42. Boyd NF, Lockwood GA, Martin LJ, et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst 1999;91:1404-8.[Abstract/Free Full Text]

This article has been cited by other articles:

				C. Atkinson, K. M Newton, E. J A. Bowles, M. Yong, and J. W Lampe Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in the United States Am. J. Clinical Nutrition, March 1, 2008; 87(3): 679 - 687. [Abstract] [Full Text] [PDF]

				B. J. Fuhrman, B. E. Teter, M. Barba, C. Byrne, A. Cavalleri, B. J. Grant, P. J. Horvath, D. Morelli, E. Venturelli, and P. C. Muti Equol Status Modifies the Association of Soy Intake and Mammographic Density in a Sample of Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 33 - 42. [Abstract] [Full Text] [PDF]

				C. Duffy, K. Perez, and A. Partridge Implications of Phytoestrogen Intake for Breast Cancer CA Cancer J Clin, September 1, 2007; 57(5): 260 - 277. [Abstract] [Full Text] [PDF]

				Y.-L. Low, A. M. Dunning, M. Dowsett, E. Folkerd, D. Doody, J. Taylor, A. Bhaniani, R. Luben, K.-T. Khaw, N. J. Wareham, et al. Phytoestrogen Exposure Is Associated with Circulating Sex Hormone Levels in Postmenopausal Women and Interact with ESR1 and NR1I2 Gene Variants Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 1009 - 1016. [Abstract] [Full Text] [PDF]

				M. Messina, W. McCaskill-Stevens, and J. W. Lampe Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst, September 20, 2006; 98(18): 1275 - 1284. [Abstract] [Full Text] [PDF]

				C. E. Wood, S. E. Appt, T. B. Clarkson, A. A. Franke, C. J. Lees, D. R. Doerge, and J. M. Cline Effects of High-Dose Soy Isoflavones and Equol on Reproductive Tissues in Female Cynomolgus Monkeys Biol Reprod, September 1, 2006; 75(3): 477 - 486. [Abstract] [Full Text] [PDF]

				C. E. Wood, T. C. Register, A. A. Franke, M. S. Anthony, and J. M. Cline Dietary Soy Isoflavones Inhibit Estrogen Effects in the Postmenopausal Breast Cancer Res., January 15, 2006; 66(2): 1241 - 1249. [Abstract] [Full Text] [PDF]

				C. E. Rufer, H. Glatt, and S. E. Kulling STRUCTURAL ELUCIDATION OF HYDROXYLATED METABOLITES OF THE ISOFLAVAN EQUOL BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY Drug Metab. Dispos., January 1, 2006; 34(1): 51 - 60. [Abstract] [Full Text] [PDF]

				C. Atkinson, C. L. Frankenfeld, and J. W. Lampe Gut Bacterial Metabolism of the Soy Isoflavone Daidzein: Exploring the Relevance to Human Health Experimental Biology and Medicine, March 1, 2005; 230(3): 155 - 170. [Abstract] [Full Text] [PDF]

				C. L. Frankenfeld, C. Atkinson, W. K. Thomas, E. L. Goode, A. Gonzalez, T. Jokela, K. Wahala, S. M. Schwartz, S. S. Li, and J. W. Lampe Familial Correlations, Segregation Analysis, and Nongenetic Correlates of Soy Isoflavone-Metabolizing Phenotypes Experimental Biology and Medicine, October 1, 2004; 229(9): 902 - 913. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frankenfeld, C. L. Articles by Lampe, J. W. Search for Related Content PubMed PubMed Citation Articles by Frankenfeld, C. L. Articles by Lampe, J. W.